IAItzhak Avital

Itzhak Avital

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Itzhak Avital has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Operative management for recurrent and metastatic adrenocortical carcinoma

    by Nicole M. Datrice, Russell C. Langan, R. Taylor Ripley, Clinton D. Kemp, Seth M. Steinberg, Bradford J. Wood, Steven K. Libutti, Tito Fojo, David S. Schrump, Itzhak Avital

    Objective: A review of all resections for recurrent or metastatic ACC was performed to identify patients who might benefit from a surgical approach, and to identify factors that might aid in prognosis among patients with metastatic disease.Summary Background Data: Adrenocortical carcinoma (ACC) is a rare tumor, with frequent recurrences and metastases even after complete resection. Chemotherapy has limited efficacy, and surgical resection of metastatic ACC remains controversial.Methods: A retrospective review was performed of all patients who underwent surgical intervention for metastatic ACC in a single tertiary center from 1977 to 2009. All available clinicopathologic data were analyzed to determine potential factors associated with response to treatment and survival.Results: Fifty‐seven patients underwent 116 procedures for recurrent or metastatic disease. Twenty‐three resections were for liver metastases, 48 for pulmonary metastases, 22 for abdominal disease including local recurrences, and 13 were for metastases at other sites. Median and 5‐year survivals from time of first metastasectomy were 2.5 years, and 41%, respectively. The median survival of patients with DFI 12 months (P = 0.015). Median survival for right versus left‐sided primaries was 1.9 years versus 3.8 years (P = 0.03). Liver metastases were more common with right‐sided primaries (67% vs. 41%, P = 0.05). Chemotherapy had no impact on survival.Conclusions: Resection of recurrent or metastatic ACC is safe, and may result in prolongation of survival in selected patients with DFI greater than 1 year. J. Surg. Oncol. 2012; 105:709–713.


  • The Role of RNA Interference in Targeting the Cancer Stem Cell and Clinical Trials for Cancer

    by Russell C. Langan, John Mullinax, Manish Raiji, Itzhak Avital

  • Isolation of Live Label-Retaining Cells and Cells Undergoing Asymmetric Cell Division via Nonrandom Chromosomal Cosegregation from Human Cancers

    by Danielle Hari, Hong-Wu Xin, Kshama Jaiswal, Gordon Wiegand, Bo-Kyu Kim, Che Ambe, Douglas Burka, Tomotake Koizumi, Satyajit Ray, Susan Garfield, et al.

    The ability to retain DNA labels over time is a property proposed to be associated with adult stem cells. Recently, label retaining cells (LRC) were indentified in cancer. LRC were suggested to be the result of either slow-cycling or asymmetric-cell-division with nonrandom-chromosomal-cosegregation (ACD-NRCC). ACD-NRCC is proposed to segregate the older template DNA strands into daughter stem cells and newly synthesized DNA into daughter cells destined for differentiation. The existence of cells undergoing ACD-NRCC and the stem-like nature of LRC remain controversial. Currently, to detect LRC and ACD-NRCC, cells need to undergo fixation. Therefore, testing the stem-cell nature and other functional traits of LRC and cells undergoing ACD-NRCC has been limited. Here, we show a method for labeling DNA with single and dual-color nucleotides in live human liver cancer cells avoiding the need for fixation. We describe a novel methodology for both the isolation of live LRC and cells undergoing ACD-NRCC via fluorescence-activated cell sorting with confocal microscopy validation. This has the potential to be a powerful adjunct to stem-cell and cancer research.


  • Cancer Stem Cells in Hepatocellular Cancer

    by Russell C. Langan, Itzhak Avital

  • Open Access

    Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways

    by Jens U. Marquardt, Chiara Raggi, Jesper B. Andersen, Daekwan Seo, Itzhak Avital, David Geller, Yun-Han Lee, Mitsuteru Kitade, Agnes Holczbauer, Matthew C. Gillen, et al.

    Epigenetic mechanisms play critical roles in stem cell biology by maintaining pluripotency of stem cells and promoting differentiation of more mature derivatives. If similar mechanisms are relevant for the cancer stem cell (CSC) model, then epigenetic modulation might enrich the CSC population, thereby facilitating CSC isolation and rigorous evaluation. To test this hypothesis, primary human cancer cells and liver cancer cell lines were treated with zebularine (ZEB), a potent DNA methyltransferase-1 inhibitor, and putative CSCs were isolated using the side population (SP) approach. The CSC properties of ZEB-treated and untreated subpopulations were tested using standard in vitro and in vivo assays. Whole transcriptome profiling of isolated CSCs was performed to generate CSC signatures. Clinical relevance of the CSC signatures was evaluated in diverse primary human cancers. Epigenetic modulation increased frequency of cells with CSC properties in the SP fraction isolated from human cancer cells as judged by self-renewal, superior tumor-initiating capacity in serial transplantations, and direct cell tracking experiments. Integrative transcriptome analysis revealed common traits enriched for stemness-associated genes, although each individual CSC gene expression signature exhibited activation of different oncogenic pathways (e.g., EGFR , SRC, and MYC). The common CSC signature was associated with malignant progression, which is enriched in poorly differentiated tumors, and was highly predictive of prognosis in liver and other cancers. Conclusion: Epigenetic modulation may provide a tool for prospective isolation and in-depth analysis of CSC. The liver CSC gene signatures are defined by a pernicious interaction of unique oncogene-specific and common stemness traits. These data should facilitate the identifications of therapeutic tools targeting both unique and common features of CSCs. (HEPATOLOGY 2011;)


  • Open Access

    Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

    by Jeremy L Davis, Prakash Pandalai, R Taylor Ripley, Russell C Langan, Seth M Steinberg, Melissa Walker, Mary Ann Toomey, Elliot Levy, Itzhak Avital

    Background: Pancreatic cancer is the fourth leading cause of cancer death in the United States. Surgery offers the only chance for cure. However, less than twenty percent of patients are considered operative candidates at the time of diagnosis. A common reason for being classified as unresectable is advanced loco-regional disease. A review of the literature indicates that almost nine hundred patients with pancreatic cancer have received regional chemotherapy in the last 15 years. Phase I studies have shown regional administration of chemotherapy to be safe. The average reported response rate was approximately 26%. The average 1-year survival was 39%, with an average median survival of 9 months. Of the patients that experienced a radiographic response to therapy, 78 (78/277, 28%) patients underwent exploratory surgery following regional chemotherapy administration; thirty-two (41%) of those patients were amenable to pancreatectomy. None of the studies performed analyses to identify factors predicting response to regional chemotherapy. Progressive surgical techniques combined with current neoadjuvant chemoradiotherapy strategies have already yielded emerging support for a multimodality approach to treatment of advanced pancreatic cancer. Intravenous gemcitabine is the current standard treatment of pancreatic cancer. However, >90% of the drug is secreted unchanged affecting toxicity but not the cancer per se. Gemcitabine is converted inside the cell into its active drug form in a rate limiting reaction. We hypothesize that neoadjuvant regional chemotherapy with continuous infusion of gemcitabine will be well tolerated and may improve resectability rates in cases of locally advanced pancreatic cancer. Design: This is a phase I study designed to evaluate the feasibility and toxicity of super-selective intra-arterial administration of gemcitabine in patients with locally advanced, unresectable pancreatic adenocarcinoma. Patients considered unresectable due to locally advanced pancreatic cancer will receive super-selective arterial infusion of gemcitabine over 24 hours via subcutaneous indwelling port. Three to six patients will be enrolled per dose cohort, with seven cohorts, plus an additional six patients at the maximum tolerated dose; accrual is expected to last 36 months. Secondary objectives will include the determination of progression free and overall survival, as well as the conversion rate from unresectable to potentially resectable pancreatic cancer. Trial Registration: ClinicalTrials.gov ID: NCT01294358


  • Open Access

    Pulmonary Resection for Metastatic Gastric Cancer

    by Clinton D. Kemp, Mio Kitano, Sid Kerkar, R. Taylor Ripley, Jens U. Marquardt, David S. Schrump, Itzhak Avital